Bristol-Myers Squibb GmbH & Co. KGaA

Kontakt: 
Arnulfstr. 29
80636 München
www.bms-onkologie.de

 

Ausgewählte Pressemitteilungen

Nivolumab Plus Ipilimumab Combination Demonstrated Superior Overall Survival

CheckMate -214 Study Evaluating Nivolumab in Combination with Ipilimumab Stopped Early for Demonstrating Overall Survival Benefit

Themen: